Why Aspirin Falls Short
About 5 to 8 percent of pregnancies involve preeclampsia. That is roughly 8 million women worldwide each year. It is a leading cause of premature birth and maternal death.
Current guidelines tell doctors to give low-dose aspirin (usually 81 to 100 milligrams per day) to women with risk factors. These include first-time pregnancy, obesity, chronic high blood pressure, or a history of preeclampsia.
But the results are mixed. Some studies show aspirin cuts the risk by 20 percent. Others show almost no benefit for certain groups.
The new review says the reason is simple. Aspirin targets one pathway in the body. But preeclampsia can start through several different biological pathways. If your preeclampsia is not driven by the pathway aspirin blocks, the drug will not stop it.
A New Way to Think About Risk
The old approach treated all pregnant women the same. High risk equals aspirin. Period.
The new approach is different. It asks a more specific question. What type of preeclampsia is this woman at risk for?
Think of it like a lock and key. Each type of preeclampsia is a different lock. Each drug is a different key. Giving everyone the same key means many locks stay closed.
The researchers call this "precision prophylaxis." It means matching the prevention strategy to the woman's specific molecular profile.
What Changes for Different Risk Groups
The review identifies three high-risk groups that need different approaches.
First, women pregnant with twins or triplets. Multiple pregnancies create a much higher load of placenta cells and particles. These particles can trigger inflammation and blood vessel damage. Standard low-dose aspirin may not be enough. The review suggests these women may need high-dose aspirin, 150 milligrams or more per day, to neutralize the extra load.
Second, women with chronic high blood pressure before pregnancy. Their blood vessel lining is already fragile. Aspirin alone may not protect it. The review proposes combining low-dose aspirin with low molecular weight heparin. This combination appears to protect the glycocalyx, which is the protective coating on blood vessel walls. Think of it like wax on a car. The heparin helps keep that wax intact.
Third, women with metabolic risks like obesity or diabetes. Their problem is often an imbalance in proteins that control blood vessel growth. The review says statins, the cholesterol-lowering drugs, may work better than metformin for this group. Statins appear to restore the balance between pro-growth and anti-growth signals in the placenta.
This does not mean pregnant women should start taking statins or heparin today.
The Research Behind the Shift
The review analyzed dozens of studies on preeclampsia prevention. It looked at why some treatments work for some women but not others.
The key insight is that preeclampsia has different "molecular endotypes." An endotype is a disease subtype defined by its underlying biology, not just its symptoms.
For example, some women develop preeclampsia because of inflammation. Others develop it because of problems with blood vessel repair. Others have issues with the placenta releasing too many particles into the bloodstream.
Each endotype needs a different drug. Aspirin works best for inflammation-driven preeclampsia. It does little for the other types.
But There's a Catch
This precision approach is not ready for your doctor's office yet.
The review is a proposal, not a clinical guideline. It lays out a roadmap for future research. But the studies needed to confirm these ideas are still ongoing.
Doctors cannot yet test a pregnant woman to determine her preeclampsia endotype. There are no simple blood tests or scans that say "this woman needs statins" or "this woman needs high-dose aspirin."
That technology is being developed. But it will take time.
If you are pregnant or planning a pregnancy, do not stop taking aspirin if your doctor prescribed it. Low-dose aspirin is safe and effective for many women.
But do ask questions. Ask your doctor why they chose aspirin for you. Ask if your specific risk factors might need a different approach.
The most important takeaway is this. Preeclampsia prevention is becoming smarter. The days of one-size-fits-all are ending. But the transition will take years.
What Happens Next
Researchers are now working on two fronts. First, they are developing tests to identify preeclampsia endotypes early in pregnancy. Second, they are running clinical trials to test the drug combinations proposed in this review.
The goal is a future where a pregnant woman gets a blood test at her first prenatal visit. The results tell her doctor exactly which prevention strategy will work for her.
That future is not here yet. But for the first time, researchers have a clear map of how to get there.
